FDA Accepts Supplement for Zituvimet by Zydus Lifesciences
The FDA has accepted the supplemental NDA for Zituvimet, a combination of Metformin Hydrochloride and Sitagliptin, submitted by Zydus Lifesciences.
Asset / Drug
Drug and asset intelligence for Zituvimet with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.